Clinical Trials Logo

Hypercholesterolemia, Familial clinical trials

View clinical trials related to Hypercholesterolemia, Familial.

Filter by:

NCT ID: NCT00134511 Completed - Clinical trials for Hypercholesterolemia, Familial

Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder

Start date: March 2005
Phase: Phase 3
Study type: Interventional

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of the lipid drug Torcetrapib/atorvastatin in patients with genetically known disorder of extremely high cholesterol

NCT ID: NCT00134485 Completed - Hyperlipidemia Clinical Trials

Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia

Start date: March 2005
Phase: Phase 3
Study type: Interventional

The Torcetrapib project was terminated on December 2, 2006 due to safety findings. To evaluate the efficacy and safety of torcetrapib/atorvastatin compared to atorvastatin alone in patients with heterozygous familial hypercholesterolemia

NCT ID: NCT00092833 Terminated - Clinical trials for Hypercholesterolemia, Familial

Investigational Drug in Patients With Hypercholesterolemia or in Patients With Sitosterolemia (0653-026)(COMPLETED)

Start date: July 2002
Phase: Phase 3
Study type: Interventional

The purpose of this study is to provide an investigational drug to patients with a specific type of hypercholesterolemia (high cholesterol) or sitosterolemia (unusually high absorption of non-cholesterol sterols) in a treatment use setting.

NCT ID: NCT00005168 Completed - Obesity Clinical Trials

Hyperapo B and Coronary Heart Disease

Start date: August 1984
Phase: N/A
Study type: Observational

To determine the role of apolipoprotein B and apolipoprotein A1 in the etiology of coronary artery disease.

NCT ID: NCT00000594 Completed - Clinical trials for Cardiovascular Diseases

NHLBI Type II Coronary Intervention Study

Start date: November 1971
Phase: Phase 3
Study type: Interventional

To determine whether lowering of cholesterol with cholestyramine in a population with Type II hyperlipidemia led to a decreased rate of progression (a regression of coronary artery disease) as demonstrated by death, myocardial infarction, or progression of disease on angiography.